Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

TPST

Tempest Therapeutics, Inc.

Tremor tracks 1 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

None right now.

Trials

  • TPSTTempest Therapeutics
    0Calm

    A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy

    Not started yetPhase 3740 patientsMain results: Dec 2028

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

0 sales (0 not pre-planned) · 0 purchases

No insider sales or purchases in the last 6 months.

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

  • Warning about being removed from the stock exchangeNews report (8-K)Nov 6, 2026
  • An executive or board member joined or leftNews report (8-K)Oct 30, 2026
  • Other newsNews report (8-K)Oct 20, 2026
  • An executive or board member joined or left; Shared information with investorsNews report (8-K)Oct 19, 2026
  • Signed a major agreement; An executive or board member joined or left; Shared information with investorsNews report (8-K)Sep 28, 2026

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.
Permission to sell new sharesPermission to sell new shares (S-3)
Sep 25, 2026
  • Signed a major agreement; Shared information with investorsNews report (8-K)Sep 17, 2026
  • Other newsNews report (8-K)Sep 16, 2026
  • Signed a major agreementNews report (8-K)Sep 15, 2026
  • An executive or board member joined or leftNews report (8-K)Aug 24, 2026
  • Permission to sell new sharesPermission to sell new shares (S-1)Aug 21, 2026
  • Other newsNews report (8-K)Aug 18, 2026
  • Quarterly reportQuarterly report (10-Q)Aug 13, 2026
  • Shared quarterly resultsNews report (8-K)Aug 13, 2026
  • Signed a major agreementNews report (8-K)Aug 13, 2026
  • Other newsNews report (8-K)Jul 28, 2026
  • Signed a major agreement; Shared information with investorsNews report (8-K)Jul 22, 2026
  • Permission to sell new sharesPermission to sell new shares (S-3)Jun 26, 2026
  • News reportNews report (8-K)Jun 23, 2026
  • An executive or board member joined or left; Shared information with investorsNews report (8-K)Jun 4, 2026
  • Signed a major agreementNews report (8-K)Jun 2, 2026
  • An executive or board member joined or leftNews report (8-K)May 29, 2026
  • Warning about being removed from the stock exchangeNews report (8-K)May 22, 2026
  • An executive or board member joined or leftNews report (8-K)May 22, 2026
  • Quarterly reportQuarterly report (10-Q)May 14, 2026
  • Shared quarterly resultsNews report (8-K)May 14, 2026